1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Phase III success for CTI's pacritinib, but second study crucial

 
• By Mandy Jackson

A statistically significant percentage of myelofibrosis patients treated with CTI BioPharma's pacritinib in the Phase III PERSIST-1 clinical trial had a 35% or greater reduction in spleen size versus best available therapy, including particularly large decreases for individuals who are unlikely to be treated effectively with the competing Incyte and Novartis Janus kinase (JAK) inhibitor Jakafi (ruxolitinib).

A statistically significant percentage of myelofibrosis patients treated with CTI BioPharma's pacritinib in the Phase III PERSIST-1 clinical trial had a 35% or greater reduction in spleen size versus best available therapy, including particularly large decreases for individuals who are unlikely to be treated effectively with the competing Incyte and Novartis Janus kinase (JAK) inhibitor Jakafi (ruxolitinib).

PERSIST-1 enrolled 327 patients with myelofibrosis regardless of platelet count levels, but the JAK2 and FMS-like tyrosine kinase 3 (FLT-3)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By Joseph Haas

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

More from Therapy Areas

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?